DDIT3 and diffuse large B-cell lymphoma: A total of 108 patients were treated for DLBCL from January 1, 2014 through May 31, 2019. Of those, we identified 21 patients with the ABC subtype who had been treated with either R-CHOP or DA-REPOCH. We reported their survival as of August 1, 2020. The characteristics of these patients at diagnosis can be seen in Table 1.